BLUTDRUCKSENKENDES MITTEL

European patent · EP3308781 · In force

Register entry

Publication number
EP3308781
Application number
EP16807590
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Jun 10, 2016
Published
Apr 18, 2018
Granted
Jan 12, 2022
Protection ends at the latest
Jun 9, 2036
Next annual fee due
Jun 30, 2027
IPC classes
A61K 31/198 (2006.01)
A23L 33/175 (2016.01)
A61K 36/8962 (2006.01)
A61P 9/12 (2006.01)
C07C 321/18 (2006.01)
Priority
JP 2015119116 12.06.2015
PCT application
PCT/JP2016/067320 10.06.2016
PCT publication
WO2016/199885 15.12.2016
Filing language
Japanese
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Jul 1, 2026

    Next annual fee due on

    Next annual fee due on
    30.06.2026 → 30.06.2027

    Published in Swissreg on 01.07.2026

  2. Jul 1, 2025

    Next annual fee due on

    Next annual fee due on
    30.06.2025 → 30.06.2026

    Published in Swissreg on 01.07.2025

  3. Jul 1, 2024

    Change

    Published in Swissreg on 01.07.2024

  4. Jul 1, 2023

    Change

    Published in Swissreg on 01.07.2023

  5. Nov 23, 2022

    Change

    Published in Swissreg on 23.11.2022

  6. Jun 30, 2022

    Change

    Published in Swissreg on 30.06.2022

  7. Jan 12, 2022

    Granted

    Published in Swissreg on 12.01.2022

Parties

Holder

WAKUNAGA PHARMACEUTICAL CO., LTD.

Wakunaga Pharmaceutical Co., Ltd.

5-36, Miyahara 4-chome Yodogawa-ku, Osaka-shi Osaka 532-0003, JP

Inventor

MORIHARA, Naoaki

Aki-Takata-shi Hiroshima 739-1195, JP

USHIJIMA, Mitsuyasu

Aki-Takata-shi Hiroshima 739-1195, JP

TAKASHIMA, Miyuki

Aki-Takata-shi Hiroshima 739-1195, JP

KODERA, Yukihiro

Aki-Takata-shi Hiroshima 739-1195, JP

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.